Backs FY25 revenue view $10.7B-$10.85B, consensus $10.78B. Backs FY25 capital expenditures $500M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics reports Q1 adjusted EPS $2.21, consensus $2.15
- Is DGX a Buy, Before Earnings?
- Quest Diagnostics price target raised to $198 from $190 at BofA
- Quest Diagnostics launches AD-Detect blood test for Alzheimer’s confirmation
- Quest Diagnostics price target raised to $189 from $178 at Mizuho